DCT
2:26-cv-12883
Aragon Pharma Inc v. Lupin Ltd
Key Events
Complaint
Table of Contents
complaint Intelligence
I. Executive Summary and Procedural Information
- Parties & Counsel:
- Plaintiff: Aragon Pharmaceuticals, Inc. (Delaware) and Janssen Biotech, Inc. (Pennsylvania)
- Defendant: Lupin Limited (India) and Lupin Pharmaceuticals, Inc. (Delaware)
- Plaintiff’s Counsel: Robinson Miller LLC
- Case Identification: 2:26-cv-12883, D.N.J., 10/01/2026
- Venue Allegations: Venue is alleged to be proper in the District of New Jersey based on Defendants' "substantial, continuous, and systematic contacts with New Jersey," including the development, manufacturing, marketing, and distribution of pharmaceutical products in the state, and the existence of regular and established places of business.
- Core Dispute: Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) to market a generic version of the prostate cancer drug Erleada® (apalutamide) constitutes an act of infringement of two U.S. patents covering apalutamide compositions and methods of treatment.
- Technical Context: The lawsuit concerns pharmaceutical treatments for prostate cancer, specifically targeting the androgen receptor, a key driver of disease progression.
- Key Procedural History: This is a Hatch-Waxman action initiated within 45 days of Plaintiffs' receipt of a Paragraph IV Notice Letter from Defendants. The complaint notes that the patents-in-suit are listed in the FDA's Orange Book as covering Erleada®. Plaintiffs also note a separate, pending litigation in the same district involving the same patents against a different pharmaceutical company.
Case Timeline
| Date | Event |
|---|---|
| 2014-12-05 | U.S. Patent No. 12,303,493 Priority Date |
| 2019-01-30 | U.S. Patent No. 12,303,497 Priority Date |
| 2025-05-20 | U.S. Patent No. 12,303,493 Issue Date |
| 2025-05-20 | U.S. Patent No. 12,303,497 Issue Date |
| 2026-08-21 | Defendants submit ANDA amendment with Paragraph IV Certification |
| 2026-08-24 | Plaintiffs receive Defendants' Paragraph IV Notice Letter |
| 2026-09-23 | Defendants produce ANDA documents to Plaintiffs |
| 2026-10-01 | Complaint Filing Date |
II. Technology and Patent(s)-in-Suit Analysis
U.S. Patent No. 12,303,493 - "Anticancer Compositions," issued May 20, 2025
The Invention Explained
- Problem Addressed: The patent identifies a problem with the existing formulation of the anticancer drug ARN-509 (apalutamide), which was a nonaqueous, lipid-based solution in softgel capsules. This formulation suffered from poor stability, having a shelf life of only six months and requiring cold chain storage (’493 Patent, col. 10:38-44).
- The Patented Solution: The invention is a pharmaceutical formulation comprising a "solid dispersion" of ARN-509 and a polymer, hydroxypropyl methylcellulose acetate succinate (HPMCAS) '493 Patent, abstract This solid-state formulation is designed to provide improved stability and a longer shelf life, eliminating the need for cold storage and potentially reducing the daily pill burden for patients '493 Patent, col. 10:45-54 The patent describes that this solid dispersion can be produced by methods like melt-extrusion or spray drying '493 Patent, abstract
- Technical Importance: By creating a stable, solid oral dosage form, the invention enhances the logistical feasibility and patient convenience of administering apalutamide, which may in turn improve therapeutic adherence and efficacy '493 Patent, col. 10:49-54
Key Claims at a Glance
- The complaint asserts independent claim 1 and dependent claims 16 and 18 '493 Patent, claims 1, 16, 18 Compl. ¶53
- Independent Claim 1 requires:
- A solid dispersion comprising (ARN-509) and hydroxypropyl methylcellulose acetate succinate (HPMCAS).
U.S. Patent No. 12,303,497 - "Anti-Androgens for the Treatment of Metastatic Castration-Sensitive Prostate Cancer," issued May 20, 2025
The Invention Explained
- Problem Addressed: The patent addresses the need for more effective treatments for patients with metastatic castration-sensitive prostate cancer (mCSPC), a stage of the disease where cancer has spread but is still responsive to hormone therapy (’497 Patent, col. 1:49-62). Standard androgen deprivation therapy (ADT) is often insufficient to halt disease progression long-term.
- The Patented Solution: The invention provides a method of treating mCSPC by administering apalutamide in combination with ADT '497 Patent, abstract The patent presents clinical trial data demonstrating that this combination therapy significantly increases both overall survival and progression-free survival compared to administering a placebo with ADT '497 Patent, col. 2:9-25 '497 Patent, FIG. 2A '497 Patent, FIG. 3A
- Technical Importance: The invention establishes a new, more effective therapeutic regimen for mCSPC that improves key clinical outcomes, offering a significant advancement over the existing standard of care.
Key Claims at a Glance
- The complaint asserts independent claim 1 and dependent claim 12 '497 Patent, claims 1, 12 Compl. ¶70
- Independent Claim 1 requires:
- A method for increasing overall survival and progression-free survival in a patient having metastatic castration-sensitive prostate cancer.
- The method comprises administering apalutamide in a therapeutically effective amount in combination with androgen deprivation therapy to the patient.
- The administration provides an increase in the overall survival rate relative to the overall survival rate of a population of patients with mCSPC administered a placebo in combination with androgen deprivation therapy.
- The administration provides an increase in the progression-free survival rate of the patient relative to the progression-free survival rate of a population of patients with mCSPC administered a placebo in combination with androgen deprivation therapy.
- The administration provides (i) an increase in overall survival and a 33% reduction in risk of death or (ii) an increase in progression free survival and a 52% reduction in risk of radiographic progression or death.
III. The Accused Instrumentality
Product Identification
- The accused instrumentality is Defendants' "Proposed ANDA Product," identified as "apalutamide tablets, for oral use, 60 mg," which is a proposed generic version of Erleada® '493 Patent, abstract Compl. ¶¶2, 46
Functionality and Market Context
- The complaint alleges the Proposed ANDA Product contains a solid dispersion of apalutamide and hydroxypropyl methylcellulose acetate succinate (HPMCAS) '493 Patent, abstract Compl. ¶55 The complaint includes a diagram showing the chemical structure of apalutamide Compl. ¶55
- Plaintiffs allege that Defendants seek FDA approval to market the Proposed ANDA Product for the same indications as Erleada®, including for the treatment of mCSPC Compl. ¶¶2, 40 The commercial context is a generic drug manufacturer seeking to enter the market by offering a lower-cost equivalent of a branded drug prior to patent expiration.
IV. Analysis of Infringement Allegations
U.S. Patent No. 12,303,493 Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A solid dispersion comprising (ARN-509) | The Proposed ANDA Product contains a solid dispersion comprising apalutamide, which is also known as ARN-509. | ¶55 | col. 10:27-31 |
| and hydroxypropyl methylcellulose acetate succinate (HPMCAS). | The Proposed ANDA Product contains a solid dispersion comprising hydroxypropyl methylcellulose acetate succinate, which is known as HPMCAS. | ¶55 | col. 10:27-31 |
U.S. Patent No. 12,303,497 Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A method for increasing overall survival and progression-free survival in a patient having metastatic castration-sensitive prostate cancer, said method comprising administering apalutamide in a therapeutically effective amount in combination with androgen deprivation therapy to the patient, | Plaintiffs allege that physicians and/or patients will be induced to practice the claimed method by using the Proposed ANDA Product, which will be labeled for use in treating mCSPC. | ¶71; ¶72 | col. 2:9-25 |
| wherein administration of the apalutamide in combination with androgen deprivation therapy provides an increase in the overall survival rate relative to the overall survival rate of a population of patients with the metastatic castration-sensitive prostate cancer, said population having been administered a placebo... | The complaint alleges that use of the Proposed ANDA Product according to its label will result in the claimed increase in overall survival rate relative to a placebo-treated population. | ¶71 | col. 2:9-25 |
| and wherein administration of the apalutamide in combination with androgen deprivation therapy provides an increase in the progression-free survival rate of the patient relative to progression-free survival rate of a population of patients with the metastatic castration-sensitive prostate cancer, said population having been administered a placebo... | The complaint alleges that use of the Proposed ANDA Product according to its label will result in the claimed increase in progression-free survival rate relative to a placebo-treated population. | ¶71 | col. 2:9-25 |
| wherein administration of apalutamide in combination with androgen deprivation therapy provides (i) an increase in overall survival and a 33% reduction in risk of death or (ii) an increase in progression free survival and a 52% reduction in risk of radiographic progression or death. | The complaint alleges that use of the Proposed ANDA Product according to its label will achieve the specified clinical outcomes. | ¶71 | col. 2:9-25 |
Identified Points of Contention
- Scope Questions ('493 Patent): While the complaint's allegations are direct, a potential dispute may arise over the definition of "solid dispersion" '493 Patent, claim 1 The court may need to determine if the defendants' formulation, as described in their ANDA, meets the patent's technical definition of a solid dispersion, which could be construed narrowly as a homogenous "solid solution" or more broadly to include less uniform mixtures '493 Patent, col. 13:23-41
- Legal Questions ('497 Patent): The infringement allegation for the '497 Patent hinges on induced infringement. A primary legal question will be whether the patent's "wherein" clauses, which recite specific clinical outcomes (e.g., a "33% reduction in risk of death"), are patent-eligible limitations of the method claim that must be met for infringement to occur. This raises the question of how infringement can be proven for a claim defined by population-level statistical outcomes.
V. Key Claim Terms for Construction
'493 Patent
- The Term: "solid dispersion" '493 Patent, claim 1
- Context and Importance: This term is the central element of the asserted composition claim. Its construction will be critical because if the Defendants' formulation does not fall within the scope of this term, there is no infringement. Practitioners may focus on this term to determine if there is any non-infringement argument based on the specific physical properties of the accused generic product.
- Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The specification defines the term broadly as "a system in a solid state... comprising at least two components, wherein one component is dispersed more or less evenly throughout the other component" '493 Patent, col. 13:23-28 This language could encompass a wide variety of physical mixtures.
- Evidence for a Narrower Interpretation: The patent also describes a "solid solution" as a preferred, "homogenous" type of solid dispersion where the system consists of "one phase" '493 Patent, col. 13:28-34 Defendants may argue that the claims should be limited to this more specific, homogenous embodiment, especially if their product can be characterized as a less-uniform mixture.
'497 Patent
- The complaint does not provide sufficient detail for analysis of specific claim terms in the '497 Patent, as the dispute will likely center on the legal theory of inducement rather than the technical meaning of individual words.
VI. Other Allegations
Indirect Infringement
- The complaint's allegations for both patents rely heavily on theories of indirect infringement.
- For the '493 Patent, Plaintiffs allege inducement and contributory infringement, stating that Defendants know the Proposed ANDA Product will be used to infringe and that the product is not a staple article suitable for substantial non-infringing use Compl. ¶57 Compl. ¶64 Compl. ¶66
- For the '497 Patent, Plaintiffs allege inducement based on the assertion that Defendants' product will be "specifically labeled for use in practicing the claims" and that Defendants know and intend for physicians to prescribe the product in an infringing manner (Compl. ¶¶72-73; Compl. ¶79).
Willful Infringement
- The complaint alleges that Defendants have actual knowledge of the patents-in-suit, citing their Paragraph IV Notice Letter which discusses the patents' listing in the FDA Orange Book Compl. ¶49 Compl. ¶59 Compl. ¶75 This alleged pre-suit knowledge forms the basis for the willfulness claim and the request for enhanced damages and attorney fees Compl. Prayer for Relief ¶ F
VII. Analyst’s Conclusion: Key Questions for the Case
- A core issue for the '493 patent will be one of validity: Given the direct allegations regarding the composition of the Proposed ANDA Product, infringement appears factually straightforward. The central conflict will likely revolve around Defendants' asserted defense, noted in their Paragraph IV certification, that the patent's claims are invalid over the prior art.
- A key legal question for the '497 patent will be one of induced infringement: Can Plaintiffs prove that Defendants' proposed product label will actively encourage physicians to perform a method that satisfies the claim's specific, population-based clinical outcome limitations? The case may turn on whether these "wherein" clauses are interpreted as requiring proof of a specific statistical result for every instance of infringement.
- An overarching question will be the impact of the proposed product's label: The content and language of the Defendants' final, FDA-approved label for their generic apalutamide will be critical evidence for determining whether they induce infringement of the '497 method patent and contribute to infringement of the '493 composition patent.
Analysis metadata